Published in Biophys J on April 21, 2010
The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol (2013) 1.88
Cysteine modification reveals which subunits form the ligand binding site in human heteromeric 5-HT3AB receptors. J Physiol (2011) 1.29
5-HT(3) receptors. J Biol Chem (2012) 1.11
Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol Pharmacol (2011) 1.10
VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors. J Pharmacol Exp Ther (2012) 0.95
The 5-HT3AB receptor shows an A3B2 stoichiometry at the plasma membrane. Biophys J (2013) 0.91
Discriminating between 5-HT₃A and 5-HT₃AB receptors. Br J Pharmacol (2013) 0.87
The 5-HT3B subunit affects high-potency inhibition of 5-HT3 receptors by morphine. Br J Pharmacol (2012) 0.85
Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site. J Biol Chem (2012) 0.85
Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors. Neuropharmacology (2013) 0.81
High-affinity fluorescent ligands for the 5-HT(3) receptor. Bioorg Med Chem Lett (2011) 0.79
Association, interaction, and replication analysis of genes encoding serotonin transporter and 5-HT3 receptor subunits A and B in alcohol dependence. Hum Genet (2013) 0.79
Ion channels gated by acetylcholine and serotonin: structures, biology, and drug discovery. Acta Pharmacol Sin (2015) 0.78
A single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors. Br J Pharmacol (2013) 0.78
Allosteric activation of the 5-HT3AB receptor by mCPBG. Neuropharmacology (2014) 0.76
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor. Bioorg Med Chem (2013) 0.75
Novel mechanism of modulation at a ligand-gated ion channel; action of 5-Cl-indole at the 5-HT3 A receptor. Br J Pharmacol (2016) 0.75
Approaching the 5-HT₃ receptor heterogeneity by computational studies of the transmembrane and intracellular domains. J Comput Aided Mol Des (2013) 0.75
Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A (1985) 68.48
Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 64.61
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature (2001) 11.78
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs. Neuron (1992) 10.25
FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties. J Mol Biol (2001) 10.02
Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques (1990) 6.90
Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res (1996) 4.79
A nomenclature for ligand-gated ion channels. Neuropharmacology (2008) 2.93
The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature (1999) 2.91
A cytoplasmic region determines single-channel conductance in 5-HT3 receptors. Nature (2003) 2.47
Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochemistry (2002) 2.22
Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene (2003) 1.67
The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J Biol Chem (1999) 1.62
The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel (review). Mol Membr Biol (2002) 1.58
Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. Proc Natl Acad Sci U S A (2005) 1.52
Locating an antagonist in the 5-HT3 receptor binding site using modeling and radioligand binding. J Biol Chem (2005) 1.44
Common determinants of single channel conductance within the large cytoplasmic loop of 5-hydroxytryptamine type 3 and alpha4beta2 nicotinic acetylcholine receptors. J Biol Chem (2006) 1.39
The role of tyrosine residues in the extracellular domain of the 5-hydroxytryptamine3 receptor. J Biol Chem (2004) 1.31
Radioligand binding methods: practical guide and tips. Am J Physiol (1993) 1.29
Prediction of 5-HT3 receptor agonist-binding residues using homology modeling. Biophys J (2003) 1.22
Different binding orientations for the same agonist at homologous receptors: a lock and key or a simple wedge? J Am Chem Soc (2003) 1.19
Molecular determinants of single-channel conductance and ion selectivity in the Cys-loop family: insights from the 5-HT3 receptor. Trends Pharmacol Sci (2005) 1.11
Molecular determinants of picrotoxin inhibition of 5-hydroxytryptamine type 3 receptors. J Pharmacol Exp Ther (2005) 1.09
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol (2003) 1.09
Antibodies against the extracellular domain of the 5-HT3 receptor label both native and recombinant receptors. Brain Res Mol Brain Res (1999) 1.07
Spatial orientation of the antagonist granisetron in the ligand-binding site of the 5-HT3 receptor. Mol Pharmacol (2005) 1.06
Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. Biophys J (2003) 1.06
Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors. Br J Pharmacol (2008) 1.06
The primer generator: a program that facilitates the selection of oligonucleotides for site-directed mutagenesis. Biotechniques (1999) 1.05
Interactions of granisetron with an agonist-free 5-HT3A receptor model. Biochemistry (2006) 1.00
Evidence for expression of heteromeric serotonin 5-HT(3) receptors in rodents. J Neurochem (2000) 0.97
Binding interactions of antagonists with 5-hydroxytryptamine3A receptor models. J Recept Signal Transduct Res (2003) 0.96
Detection of human and rodent 5-HT3B receptor subunits by anti-peptide polyclonal antibodies. BMC Neurosci (2006) 0.95
Molecular dynamics simulations of GABA binding to the GABAC receptor: the role of Arg104. Biophys J (2008) 0.92
The loop C region of the murine 5-HT3A receptor contributes to the differential actions of 5-hydroxytryptamine and m-chlorophenylbiguanide. Biochemistry (2005) 0.87
The 5-hydroxytryptamine type 3 (5-HT3) receptor reveals a novel determinant of single-channel conductance. Biochem Soc Trans (2004) 0.83
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
5-HT3 receptors. Curr Pharm Des (2006) 1.49
Cysteine modification reveals which subunits form the ligand binding site in human heteromeric 5-HT3AB receptors. J Physiol (2011) 1.29
Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol Pharmacol (2011) 1.10
The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors. Br J Pharmacol (2007) 1.07
Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors. Br J Pharmacol (2008) 1.06
Loop B is a major structural component of the 5-HT3 receptor. Biophys J (2008) 0.96
VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors. J Pharmacol Exp Ther (2012) 0.95
Discriminating between 5-HT₃A and 5-HT₃AB receptors. Br J Pharmacol (2013) 0.87
A single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors. Br J Pharmacol (2013) 0.78
Unbinding pathways of an agonist and an antagonist from the 5-HT3 receptor. Biophys J (2005) 0.76